Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01890473 · ClinicalTrials.gov registry record · Phase 1

Study to Characterize the Pharmacokinetics of a Single Dose of SC Abatacept 125 mg Using the BD Autoinjector or the Prefilled Syringe

A Phase 1 study of Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 1
Development phase
356
Enrollment target
20
Study locations

NCT01890473 is a Phase 1 study of Rheumatoid Arthritis that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 356 participants, below the 4,689-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01890473, a Phase 1 study of Rheumatoid Arthritis, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 1
Development phase
356 participants
Enrollment target
20
Study locations

Study Summary

The primary purpose of the protocol is to describe the pharmacokinetics of a single dose of Abatacept 125 mg in Rheumatoid Arthritis patients delivered via the autoinjector device or the approved prefilled syringe.

Conditions Studied

Rheumatoid Arthritis

Interventions

  • DRUG Abatacept

Study Locations (20)

North Carolina

  • Djl Research, Pllc - Charlotte
  • Wake Research Associates - Raleigh
  • Pmg Research Of Salisbury - Salisbury
  • Pmg Research Of Wilmington Llc - Wilmington

Córdoba Province

  • Local Institution - Córdoba
  • Local Institution - Córdoba

Alabama

  • Rheumatology Associates Of North Alabama, P.C. - Huntsville

Colorado

  • Immunoe Int'L Research Ctrs - Centennial

Florida

  • Covance Cru Inc - Daytona Beach

Kansas

  • Heartland Research Associates, Llc - Wichita

Massachusetts

  • Clinical Pharmacology Study Group - Worcester

Nebraska

  • Physician Research Collaboration, Llc - Lincoln

Trial Details

FieldValue
Enrollment Target 356 participants
Start Date 2013-07
Est. Completion 2014-11
Phase Phase 1

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01890473

The ClinicalTrials.gov registry entry for NCT01890473 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 356 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,689-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (92% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which Abatacept is the first listed.

NCT01890473 reports 20 study locations spanning 16 distinct geographic areas - top geographies include North Carolina, Córdoba Province, Alabama.

Frequently Asked Questions

What is clinical trial NCT01890473 about?

NCT01890473 is a clinical study titled "Study to Characterize the Pharmacokinetics of a Single Dose of SC Abatacept 125 mg Using the BD Autoinjector or the Prefilled Syringe". The primary purpose of the protocol is to describe the pharmacokinetics of a single dose of Abatacept 125 mg in Rheumatoid Arthritis patients delivered via the autoinjector device or the approved prefilled syringe.

What is the current status of trial NCT01890473?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 356 participants. The study started on 2013-07. Estimated completion is 2014-11.

What conditions does trial NCT01890473 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis.

What interventions are being tested in trial NCT01890473?

The interventions under investigation include: Abatacept (DRUG).

Who is sponsoring clinical trial NCT01890473?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01890473 being conducted?

This trial has 20 study locations across Alabama, Colorado, Florida, Kansas, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Rheumatoid Arthritis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.